James Emmett Young Purchases 24,000 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young purchased 24,000 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was bought at an average cost of $5.40 per share, for a total transaction of $129,600.00. Following the completion of the purchase, the chief financial officer now directly owns 24,000 shares in the company, valued at approximately $129,600. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

TriSalus Life Sciences Stock Up 4.5 %

NASDAQ TLSI opened at $5.11 on Friday. The stock’s 50 day moving average is $4.57 and its 200 day moving average is $4.75. TriSalus Life Sciences, Inc. has a twelve month low of $3.50 and a twelve month high of $10.42. The firm has a market capitalization of $155.80 million, a PE ratio of -2.05 and a beta of 0.51.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds have recently added to or reduced their stakes in the stock. Walleye Capital LLC bought a new stake in TriSalus Life Sciences in the third quarter worth $66,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences in the third quarter worth $92,000. Vestcor Inc bought a new stake in TriSalus Life Sciences in the third quarter worth $108,000. MSD Partners L.P. bought a new stake in TriSalus Life Sciences in the third quarter worth $184,000. Finally, Geode Capital Management LLC boosted its holdings in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares in the last quarter. 2.58% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TLSI. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective on the stock. Northland Securities began coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective on the stock. Finally, Canaccord Genuity Group cut their price objective on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.